Interfering with the adenosine pathway via blockade of the CD39/CD73 axis or adenosine receptors on T cells within the tumor microenvironment might be another promising therapeutic strategy to increase the function/potency of the DP CD8 TIL and this pathway is currently being tested in cancer-bearing hosts20. The gene discussed is CD8A; the disease is cancer.